NeuraWorx Medical Technologies, Inc.

Clinical-stage neurotech developing bioelectronic devices like Cerebrovascular Pacing System to improve brain fluid dynamics for CNS disorders.

Website: https://neuraworx.com

Cover Block

Attribute	Value
Company Name	NeuraWorx Medical Technologies, Inc.
Tagline	Clinical-stage neurotech developing bioelectronic devices like Cerebrovascular Pacing System to improve brain fluid dynamics for CNS disorders.
Headquarters	Excelsior, MN, USA
Founded	2021
Stage	Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Chris Minar, Dr. Kip Ludwig, Dr. Justin Williams [Business Wire, Dec 2025]
Funding Label	Seed

What an Investor Needs First

NeuraWorx Medical Technologies is a clinical-stage neurotech startup that recently secured an oversubscribed seed round to develop bioelectronic devices aimed at treating central nervous system disorders by enhancing the brain's natural waste-clearance system [Business Wire, Dec 2025].

The company's core technology, the Cerebrovascular Pacing System, originated from research at the University of Wisconsin-Madison. It targets glymphatic function, which is implicated in conditions like Alzheimer's disease and traumatic brain injury [VC News Daily, Dec 2025]. This approach of using non-invasive cranial nerve stimulation to modulate brain fluid dynamics during sleep positions the company in a distinct niche within the broader neurostimulation and brain health device market.

The founding team includes Chris Minar, Dr. Kip Ludwig, and Dr. Justin Williams. The company's seed financing was led by Nexus NeuroTech Ventures, with participation from Foothill Ventures, Verve HealthTech Fund, and the Wisconsin Alumni Research Foundation [Business Wire, Dec 2025].

Over the next 12-18 months, key milestones will center on advancing from the clinical-stage to initiating early human feasibility studies. The company is hiring a Clinical and Regulatory Lead [NeuraWorx].

Data Accuracy: YELLOW -- Core company facts and funding are confirmed by a primary press release; some technology claims are single-sourced or from company materials.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Chris Minar, Dr. Kip Ludwig, Dr. Justin Williams
Funding	Seed (2025)

Inside the Company

NeuraWorx Medical Technologies, Inc. is a clinical-stage neurotechnology company founded in 2021 and headquartered in Excelsior, Minnesota [Business Wire, Dec 2025]. The company's core intellectual property originated from research at the University of Wisconsin-Madison and focuses on non-invasive cranial nerve stimulation to modulate brain fluid dynamics [VC News Daily, Dec 2025]. The company's primary public milestone to date is the close of an oversubscribed seed funding round in December 2025, led by Nexus NeuroTech Ventures [Business Wire, Dec 2025].

Data Accuracy: YELLOW -- Company details and founding year confirmed by a primary press release; university origin cited by a secondary outlet. Founders named in release but no independent corroboration of backgrounds.

Under the Hood

NeuraWorx is developing a hardware-first approach to modulating brain physiology. The company's primary focus is the Cerebrovascular Pacing System, a proprietary bioelectronic device designed to non-invasively stimulate cranial nerves during sleep [Business Wire, Dec 2025]. The intended mechanism is to enhance cerebrovascular vasomotion, theorized to improve the flow of cerebrospinal fluid and the function of the glymphatic system [Creative Destruction Lab]. This targets the clearance of metabolic toxins like beta-amyloid and tau proteins implicated in neurodegenerative conditions [VC News Daily, Dec 2025]. The initial product form factor appears to be a wearable neurostimulation platform, described in some sources as a mouthguard-like device [Creative Destruction Lab]. A job listing for a Clinical and Regulatory Lead indicates active work on building a clinical engine and an FDA strategy for early human studies focused on traumatic brain injury and CNS disorders [NeuraWorx].

Data Accuracy: YELLOW -- Core product claims are consistent across multiple press releases and a program profile, but technical specifications, development stage, and preclinical data are not publicly disclosed.

Market Research and Opportunity

The market for non-invasive neurotechnology is expanding, driven by a growing population of patients with neurodegenerative conditions and a persistent lack of effective pharmacological treatments. The company's primary targets are Alzheimer's disease and traumatic brain injury. The global Alzheimer's disease therapeutics market was valued at approximately $7.3 billion in 2023 [Grand View Research, 2023]. The global traumatic brain injury treatment market size was reported at $3.4 billion in 2022 [Precedence Research, 2023]. Key demand drivers include the aging global population and increasing scientific validation of the glymphatic system's role in brain health [University of Rochester Medical Center]. As a medical device company, NeuraWorx must navigate the FDA's regulatory framework for Class II or III devices.

Data Accuracy: YELLOW -- Market sizing figures are from analogous, broad therapeutic areas, not the specific bioelectronic segment. Scientific tailwinds are well-documented in academic literature.

Competition and Substitutes

NeuraWorx enters a neurotechnology field defined by high scientific ambition and significant regulatory hurdles. It faces established therapeutic approaches and adjacent bioelectronic platforms. The competitive map includes pharmaceutical incumbents, invasive devices like deep brain stimulators, and non-invasive therapies like transcranial magnetic stimulation (TMS) or transcutaneous vagus nerve stimulation (tVNS) [Business Wire, Dec 2025]. The company's stated defensible edge rests on its specific biological target, the glymphatic system, and its proposed mechanism of enhancing cerebrovascular vasomotion during sleep [Business Wire, Dec 2025].

Data Accuracy: YELLOW -- Competitive analysis is inferred from the company's stated technology focus and general market knowledge, as no direct competitors are named in sources. The investor backing and technology description are confirmed.

Opportunity

If NeuraWorx can demonstrate clinical efficacy, it could unlock a multi-billion dollar opportunity in treating neurodegenerative diseases. The headline opportunity is to establish a new standard of care for glymphatic system enhancement. The company's seed funding from specialized neurotech investors like Nexus NeuroTech Ventures and Corundum Neuroscience provides domain-specific validation [Business Wire, Dec 2025] [Corundum Neuroscience].

Scenario	What happens	Catalyst	Why it's plausible
TBI First-Mover	NeuraWorx secures FDA breakthrough designation for its wearable device as a therapeutic for post-concussion syndrome.	Successful completion of the initial clinical feasibility study in partnership with Corundum Neuroscience [Medical Alley].	TBI represents a clear, near-term clinical need with a potentially faster regulatory pathway.
Platform Expansion	The core pacing technology proves adaptable, leading to a suite of bioelectronic products for different sleep-related neurological indications.	Publication of positive proof-of-concept data showing the technology's impact on multiple biomarkers of brain fluid dynamics.	The underlying science is indication-agnostic [Creative Destruction Lab].

Data Accuracy: YELLOW -- The opportunity analysis is based on public descriptions of the technology and investor composition, but clinical efficacy, regulatory pathways, and market capture remain unproven and forward-looking.

Sources

[Business Wire, Dec 2025] NeuraWorx Closes Oversubscribed Seed Round Led by Nexus NeuroTech to Advance Neurotechnology Therapy for CNS Disorders | https://www.businesswire.com/news/home/20251217796461/en/NeuraWorx-Closes-Oversubscribed-Seed-Round-Led-by-Nexus-NeuroTech-to-Advance-Neurotechnology-Therapy-for-CNS-Disorders
[VC News Daily, Dec 2025] NeuraWorx Medical Technology Nabs Seed Round | https://vcnewsdaily.com/neuraworx-medical-technology/venture-capital-funding/bvjthyhxwg
[Creative Destruction Lab] NeuraWorx | https://creativedestructionlab.com/companies/neuraworx/
[NeuraWorx] NeuraWorx - About Us | https://sites.google.com/neuraworx.com/neuraworx/about-us
[NeuraWorx] NeuraWorx - Solution | https://www.neuraworx.com/solution
[NeuraWorx] Jobs (List) | Neuraworx | https://www.neuraworx.com/jobs
[LinkedIn] NeuraWorx | LinkedIn | https://www.linkedin.com/company/neuraworx
[University of Toronto Entrepreneurship] University of Toronto Entrepreneurship | NeuraWorx | https://entrepreneurs.utoronto.ca/startup/neuraworx/
[Corundum Neuroscience] Companies - Corundum Neuroscience | https://cnsfund.com/companies/
[Medical Alley] NeuraWorx Partners with Corundum Neuroscience to Initiate Clinical Feasibility Study, Develop Innovative Neurological Disease Treatment | https://medicalalley.org/neuraworx-partners-with-corundum-neuroscience-to-initiate-clinical-feasibility-study-develop-innovative-neurological-disease-treatment/
[Grand View Research, 2023] Alzheimer's Disease Therapeutics Market Size, Share & Trends Analysis Report | https://www.grandviewresearch.com/industry-analysis/alzheimers-disease-therapeutics-market
[Precedence Research, 2023] Traumatic Brain Injury Treatment Market Size, Growth, Report 2023-2032 | https://www.precedenceresearch.com/traumatic-brain-injury-treatment-market
[University of Rochester Medical Center] The Brain's Waste-Removal System | https://www.urmc.rochester.edu/news/story/the-brains-waste-removal-system

Articles about NeuraWorx Medical Technologies, Inc.

A Mouthguard to Clear the Brain — NeuraWorx is betting a non-invasive neurostimulation device can treat Alzheimer's and TBI by improving the brain's nightly cleaning cycle.

View on Startuply.vc